January 15, 2018

No Image

LinkedIn Co-Founder On What Resolutions Silicon Valley Should Make For 2018

Between sexual harassment scandals, fake ads and stronger calls for regulation, Big Tech had a rocky year in 2017. LinkedIn Co-founder and venture capitalist Reid Hoffman talks with NPR’s Kelly McEvers about resolutions Silicon Valley should make in 2018.

KELLY MCEVERS, HOST:

And in All Tech Considered this week, we are talking about what is ahead for the tech industry in 2018.

(SOUNDBITE OF ULRICH SCHNAUSS’ “NOTHING HAPPENS IN JUNE”)

MCEVERS: In some ways, 2017 was a great year for tech companies – big growth, big profits. In other ways, it was a pretty bad year. Facebook, Twitter and Google admitted that Russian operatives used their platforms to promote fake stories during the election. There were sexual harassment scandals and criticism of the fact that white men still basically run the place.

My guest is someone who knows many of the leaders of these companies, Reid Hoffman. He is a venture capitalist. He’s the co-founder of LinkedIn. And he’s got some thoughts about how Silicon Valley can do better in 2018. Welcome to the show.

REID HOFFMAN: It’s great to be here.

MCEVERS: Up until now, tech companies have not been super great at taking responsibility for their problems. Do you think that this is the year of reckoning for tech companies?

HOFFMAN: Well, I hope that it’s actually a year of growth. I think actually part of what the tech companies are learning is they started as challengers, these kind of, you know – think of it as young teenagers with good ideas…

MCEVERS: Yeah.

HOFFMAN: …Trying to prove themselves. And now they realize I think, no, actually, in fact, we’re the incumbents. We’re the providers of the infrastructure. We have influence in the national dialogue, and we need to upgrade our play. And I think you can see that as the changing messages from them throughout the year. The way I like to look at this is – I have a funny phrase. It’s Spider-Man ethics. With power comes responsibility. With great power comes great responsibility.

And I think there’s beginning to have that recognition of, we have this responsibility, and we know that we need to act now both in conversation with society and societies and also to make sure that, like, there’s a higher level of trust and reliability and information and in a kind of – a sense of safety and security in your participation in these online networks and communities.

MCEVERS: Last year you came out with a decency pledge, and it was aimed at stopping sexual harassment in the industry. And one of the things you talked about was how much power venture capitalists have over entrepreneurs, entrepreneurs who frankly need the money (laughter), right?

HOFFMAN: Yeah.

MCEVERS: What’s being done about that? Like, how – you’re not going to undo that system, the way things work in that industry. So how do you address the problem?

HOFFMAN: Well, so the decency pledge is meant to be a – kind of a first step to just have a whole bunch of people say, look; I will not do business with people who are, you know, sexual predators, harassers, abusing their position of power in any capacity. And then everyone can make the public statement to that and that part of that public statement is then not only am I articulating a voice, but I can also be held accountable by the people who know me and see what’s going on.

I think the thing that we need to move from is – you know, last year’s decency pledge was very much of the, look; here’s a baseline that we can all do to step forward as individuals. To react to this, I think we now need to move from that reactive game to a proactive game.

MCEVERS: I just want to be really specific. Like, is that a step that’s led to any change, you know, that you can point to, any examples?

HOFFMAN: Well, I think one of the things that was really awesome is a large number of the powerful VCs in the Valley all publicly signed up to it.

MCEVERS: Yeah.

HOFFMAN: They all said, hey, I’m taking this, too. So I do think – I’ve heard from women entrepreneur friends of mine, women investor friends of mine that the atmosphere has become much more conducive to being able to speak up. And I do think that people are paying attention to – is, like, not only do we protect the victims, but we also try to fix the system. And we try to say, we have a zero tolerance around, you know, sexual harassment, sexual predators trying to abuse these power relationships. And so I think at least it’s moved the culture in the right direction. And I’ve heard good signs and conversation. I don’t have a dashboard that I could share.

MCEVERS: Recently some Apple investors urged the company to address concerns that its technology was hurting children. You know, there’s been a lot of fear out there – right? – that tech is addictive and it’s harmful or, at the very least, it’s replacing, you know, human interactions. Do you think one day we will think of tech companies the way we think of big tobacco – you know, this idea of, like, selling a dangerous product without consequences, without remorse at least?

HOFFMAN: Look; so technology always has some rough edges and downsides as well as upsides. But overall, you know, I’m glad we have it. I’m glad we’re more globally connected. I’m glad we have – even though it’s an information overload, (laughter) I’m glad we have a lot of information and can do searches and find information on things.

And you know, I tend to think that a lot of this tends to be older generations. Like, we feel, like, addicted and overwhelmed, but then the younger generations learn and adapt. So I tend to think that people are adaptive. And we can improve the technology to be net massively positive. So I think the chance that future technology is looked at as Big Tobacco is almost zero.

MCEVERS: But it puts the onus on the people who are using it – right? – to sort of adapt. And it puts a lot of, like, faith in you guys to do good. And I think that’s the hard sell right now, right?

HOFFMAN: Well, so that’s a little bit of the reason why was saying I think the broad move is towards more transparency. And either the industry will adopt ways of being transparent, which I hope and I’m pushing for. Or the government will say, well, OK, since you’re not actually being sufficiently disclosive to make sure that we don’t feel like we’re being manipulated and so forth, then we’re going to establish some rules. And the rules may limit your ability to innovate and create great new things for the world and for us, but c’est la vie.

MCEVERS: Yeah.

HOFFMAN: But I have faith that part of what I’m seeing happening, as I mentioned in the beginning, in 2017 is that the technologists and the technology companies are going, hey, no, we have responsibilities here. Let’s try to figure them out.

MCEVERS: Do you think it’s time in 2018 for, you know, more regulation?

HOFFMAN: Well, my big worry is that the most common pattern in regulation is to lock the past in slow motion against the future.

MCEVERS: Right.

HOFFMAN: And, A, I think the future’s very good for us – you know, what we can invent in precision medicine and what we can invent in anything from new communications technologies to autonomous vehicles and so forth. The second point of it is – is actually, you know, nations and groups are in competition. So if we say, well, we’re going to slow down our tech development, (laughter) you know, I don’t think other countries – China, et cetera – I don’t think they will be.

Now, that being said, if you said, OK, you know, we got to do some regulation – must do – what would it be? It would be like, well, try to demand some more transparency on the variables that most matter to you, like how much, you know, for example, election hacking is actually going on on your platform, (laughter) right?

MCEVERS: Right, yeah.

HOFFMAN: And what are you doing about it?

MCEVERS: Yeah.

HOFFMAN: And you need to be transparent about that. It’s not that we say, no election hacking. It’s – we say, you’ve got to give us good reports about what’s going on and how you’re making progress and what you’re doing about it. And I think that would be the kind of thing that I think – I hope tech companies will do more voluntarily. And I also think that if you – if I were to start doing anything because I’m so concerned about technology being part of the solution as opposed to part of the problem – that we don’t slow down our path to the solution.

MCEVERS: Reid Hoffman is a partner at the Silicon Valley venture capital firm Greylock. He also hosts the Masters of Scale podcast. Thanks for being with us.

HOFFMAN: Awesome to be here.

(SOUNDBITE OF CUT CHEMIST SONG, “THE GARDEN”)

Copyright © 2018 NPR. All rights reserved. Visit our website terms of use and permissions pages at www.npr.org for further information.

NPR transcripts are created on a rush deadline by Verb8tm, Inc., an NPR contractor, and produced using a proprietary transcription process developed with NPR. This text may not be in its final form and may be updated or revised in the future. Accuracy and availability may vary. The authoritative record of NPR’s programming is the audio record.

Let’s block ads! (Why?)


No Image

For Once, The Minnesota Vikings Could Be A Team Of Destiny

The NFL team that could never catch a playoff break finally got one. In their NFC Divisional Round matchup, the Minnesota Vikings pulled off a miracle win against the New Orleans Saints. NPR’s Kelly McEvers speaks with Ben Goessling, who covers the team for the Star Tribune.

KELLY MCEVERS, HOST:

There’s sad, and then there’s the playoff history of the Minnesota Vikings. Despite having some of the greatest teams in NFL history, the Vikings have never won a title. In fact, they were the first team to lose four Super Bowls. You’ve heard of the Hail Mary pass, right? Well, you can think the Vikings for that. The phrase Hail Mary pass was first used in 1975 after the Dallas Cowboys’ last-second miracle touchdown pass beat the Vikings. So last night, with the Vikings trailing the New Orleans Saints going down to the final play, most fans thought it was going to be yet another awful moment until it wasn’t.

(SOUNDBITE OF ARCHIVED RECORDING)

PAUL ALLEN: Case on a deep throw, steps up in the pocket. He’ll fire to the right side, caught by Diggs.

UNIDENTIFIED SPORTSCASTER: (Screaming) Oh, my God, oh, my God, no way.

ALLEN: (Screaming) At the 30, 10 – touchdown.

UNIDENTIFIED SPORTSCASTER: (Screaming) What a miracle finish.

ALLEN: (Screaming) Are you kidding me? It’s a Minneapolis miracle.

UNIDENTIFIED SPORTSCASTER: (Screaming) No way.

MCEVERS: Could that Minneapolis miracle lead to the first Vikings Super Bowl title? To talk about that, we turn to Ben Goessling, who covers the Vikings for the Star Tribune. Hey, Ben.

BEN GOESSLING: Hi. How are you?

MCEVERS: Good. So you are a native Minnesotan. Can you explain how bad things have actually been over the years?

GOESSLING: I guess I always put it this way. It’s appropriate in some ways that Charles Schulz, the creator of “Peanuts,” is from Minnesota because obviously everybody knows the skit in “Peanuts” where Charlie Brown thinks he’s going to get to kick the football. And every time he gets his hopes up and then Lucy pulls the ball out, he ends up sitting on the ground, you know, sort of wondering what just happened. And that really epitomizes the Vikings’ experience in the playoffs. I mean, every time they get close, something happens. So I mean, really that’s what made yesterday so remarkable.

MCEVERS: What’s it like in Minnesota right now?

GOESSLING: People are on cloud 9 right now. To be in that stadium yesterday when they scored that touchdown, it was just kind of this mixture of shock and exultation in a lot of ways. And you see that kind of spilling forward into today. People are, you know, all over social media, raving about the game as people posted videos of where they were, you know, what they were doing when they when the game ended, you know, what their reaction to the play was. There were people out doing snow angels.

MCEVERS: (Laughter).

GOESSLING: And it was no small feat given the fact it was sub-zero temperatures for most of the day and we got a bunch of snow. So it’s the kind of win, as a couple of players said yesterday, you almost have to go forward now and make it to the Super Bowl and win it. You don’t want to waste something like that and what it meant for fans. And it’s quite a remarkable thing for people around here that are used to (laughter) suffering for a long time.

MCEVERS: We should say that the Super Bowl will be in Minneapolis this year.

GOESSLING: It will.

MCEVERS: So if the Vikings win next weekend, they’ll be the first host team to actually play in the Super Bowl. I mean, does it feel like with that plus last night, things are finally coming together? Or do you not want to say anything and jinx it?

GOESSLING: Well, I mean, players certainly have been asked that question. Does this feel like a team of destiny? And you know, the number of things they’ve had go wrong in the past – a lot of those could’ve happened this year. They lose their starting quarterback, Sam Bradford, after week one. Dalvin Cook, their first pick in the draft, the running back, goes down in week four. I mean, a lot of these injuries that you think, OK, this is going to be what derails them really haven’t.

So you know, it’s going to be very interesting to see what the Super Bowl is like because, you know, the NFL tries to do everything they can to make it as neutral an environment as possible. But the Vikings are going to have some built-in advantages if they’re in that game. It really would be a one-of-a-kind environment for a Super Bowl if they make it. And you know, at this point, you know, obviously we root for stories as much as anything, and it would be a fantastic story if they make it.

MCEVERS: Ben Goessling covers the Vikings for the Star Tribune. Thanks so much.

GOESSLING: Thank you – enjoyed it.

(SOUNDBITE OF JAMES MCLEOD’S “SKOL, VIKINGS”)

Copyright © 2018 NPR. All rights reserved. Visit our website terms of use and permissions pages at www.npr.org for further information.

NPR transcripts are created on a rush deadline by Verb8tm, Inc., an NPR contractor, and produced using a proprietary transcription process developed with NPR. This text may not be in its final form and may be updated or revised in the future. Accuracy and availability may vary. The authoritative record of NPR’s programming is the audio record.

Let’s block ads! (Why?)


No Image

Box Office Report: Spielberg's 'The Post' Expansion Scoops Other New Releases at Box Office

The Post

Here’s your estimated 3-day box office returns (new releases bolded):

1. Jumanji: Welcome to the Jungle – $27.0 million ($283.1 million total)

2. The Post – $18.6 million ($23.0 million total)

3. The Commuter – $13.4 million ($13.4 million total)

4. Insidious: The Last Key – $12.1 million ($48.3 million total)

5. The Greatest Showman – $11.8 million ($94.5 million total)

6. Star Wars: The Last Jedi – $11.2 million ($591.5 million total)

7. Paddington 2 – $10.6 million ($10.6 million total)

8. Proud Mary – $10.0 million ($10.0 million total)

9. Pitch Perfect 3 – $5.6 million ($94.6 million total)

10. Darkest Hour – $4.5 million ($35.73 million total)

The Big Stories

Weekend two of 2018 is not much different than weekend one except (1) there are a lot more new movies to see and (2) there’s a holiday on Monday. People went to see the new movies but they were still clearly interested in catching up on the movies that were dominating at the end of 2017. Aside from that, though, at least one of the season’s major Oscar contenders finally expanded into wide release and had an opening that should be very encouraging with nominations just around the next weekend corner.

Publish or Perish

[embedded content]

Steven Spielberg’s The Post started filming last June and was put into limited release in late December. While he continues to work on Ready Player One, which he filmed before and will be released on March 30, Spielberg felt the story of a corrupt, lying President who tried to shut down press freedom may have had some significance in our time. What could have given him that idea? The historical prequel (of sorts) to All the President’s Men had made nearly $4.5 million in the 21 days leading up to this weekend, starting with just nine theaters and expanding to 36 last week. This weekend it moves into 2,819 and once again it couldn’t feel more timely.

Spielberg, without question, is one of our greatest living directors (and you can put him up against most of the passed-on ones as well.) Don’t take my word for it, though, as evidenced by his critical score at Rotten Tomatoes since just 2001:

Catch Me If You Can (96%), Minority Report (91%), Bridge of Spies (91%), Lincoln (90%), The Post (88%), Munich (77%), Indiana Jones and the Kingdom of the Crystal Skull (77%), War Horse (76%), The BFG (75%), The Adventures of Tintin (74%), War of the Worlds (74%), A.I.: Artificial Intelligence (73%), The Terminal (60%).

Not a rotten tomato in the batch overall with an 80.1% average. Mathematically, four out of five critics think the man makes good movies, and we’re not even listing Jaws, Close Encounters, Raiders of the Lost Ark, E.T. and Jurassic Park (to name just a few.) The box office numbers these days can’t entirely compare to those films, which have alternated between fantasy and drama. The Post‘s $18.6 million weekend is firmly between Bridge of Spies‘ $15.3 million start and The Terminal‘s $19 million (which occurred in June of 2003.)

When Lincoln went wide in just its second week in mid-November 2012, it made $21 million that weekend and played into April to the tune of $182.2 million. The Post didn’t have the advantage of the full holiday season to boost its total and its opening might not be quite in the same league for Tom Hanks as Sully ($35 million) and Captain Phillips ($25.7 million). But we should expect the word-of-mouth to be strong and the numbers to not trail off too far once the film gets nominations for Best Picture and Actress (and possibly Director and Actor, though slightly less certain) and head somewhere in the vicinity of $100 million or more.

Tales of the Top Ten

[embedded content]

It was certainly a packed week at the box office. The best of the newest of newbies turned out to be The Commuter, Liam Neeson’s fourth collaboration with Jaume Collet-Serra. It opened to slightly better than their last film together, Run All Night ($13.4 vs. $11 million.) Comparatively, it’s critical and audience scores are closest to Jack Ryan: Shadow Recruit from 2014, which could give The Commuter about $40 million when it finishes its domestic run. It will need to pick up a bit more international steam to satisfy its $30 million budget.

Paddington 2, meanwhile, is hoping to follow a similar path to the original. It’s already behind with a $10.6 million weekend despite a perfect 100%. It made $25.4 million over the four-day MLK weekend in 2015. Warner Bros. was already behind with this being a late pickup from the remaining catalog of the Weinstein Co. Regardless if it matches even just the original’s multiple (which would put it at about $43 million domestically), it’s already made over $125 million internationally. (The original made $183 million overseas.) Meanwhile, Screen Gems’ Proud Mary did not screen for critics (it currently has a 28% with those who caught up with it) and it mustered up a $10 million three-day weekend. The ceiling is not very high for the $14 million budgeted film and with limited international prospects this should be Sony’s first loser of the year.

Not that they care much given the incredible success of Jumanji: Welcome to the Jungle. By next weekend it will be over $300 million and passing Skyfall on Sony’s all-time domestic grossing chart. (The James Bond film is still Sony’s all-time worldwide grosser.) It is even still ahead of the pace of Spider-Man: Homecoming which could put this third on the studio’s all-time list behind just Spider-Man and Spider-Man 2. The film is over $666 million worldwide which ranks 11th all-time for Sony. Star Wars: The Last Jedi, meanwhile, is still Jumanji times two with $600 million domestic expected by this Friday and $1.26 billion worldwide to date. It will be passing Frozen soon to become ninth all-time on the global chart. Fox and Universal also have films hitting the $100 million milestone in the next four to eight days with The Greatest Showman and Pitch Perfect 3. The former will still need roughly another $75 million to recoup its extravagant $84 million budget. Finally, in a lesser milestone, Insidious: The Last Key will be passing the $50 million mark this week despite a 59% drop.


If you want to listen to Erik Childress’ Holiday Box Office Prediction Show, you can download the podcast.

Erik Childress can be heard each week evaluating box office on WGN Radio with Nick Digilio as well as on Business First AM with Angela Miles and his Movie Madness Podcast.

[Box office figures via Box Office Mojo.]

Let’s block ads! (Why?)


No Image

For Now, Sequencing Cancer Tumors Holds More Promise Than Proof

Ben and Tara Stern relax at home in Essex, Md. Ben was diagnosed with glioblastoma in 2016. After conventional treatment failed to stop the tumor, Ben tried an experimental drug.

Meredith Rizzo/NPR

hide caption

toggle caption

Meredith Rizzo/NPR

People diagnosed with cancer understandably reach for the very best that medical science has to offer. That motivation is increasingly driving people to ask to have the DNA of their tumors sequenced. And while that’s useful for some malignancies, the hype of precision medicine for cancer is getting far ahead of the facts.

It’s easy to understand why that’s the case. When you hear stories about the use of DNA sequencing to create individualized cancer treatment, chances are they are uplifting stories. Like that of Ben Stern.

In the spring of 2016, Stern was diagnosed with a deadly brain cancer, glioblastoma. His doctors at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins promptly treated him with surgery, then over the months, chemotherapy and radiation. He even got on a clinical trial to see if a leading edge drug called a checkpoint inhibitor would work.

Ben Stern found out abruptly that wasn’t doing the trick either, when he was struck with a seizure. “My whole right side clenched up and [my wife] Tara had called 911 in the middle of it.”

The tumor had grown back, so surgeons went in again to remove what they could. Tara said the next month’s appointment showed the surgery hadn’t worked, either.

“The tumor had already grown back and it was already bigger than the original size tumor that we had found the previous May,” Tara Stern says. This staggering regrowth took only five weeks.

The Sterns hang up images of Ben’s brain tumor, shown on the right (white) in each image, and also five weeks after treatment.

Meredith Rizzo/NPR

hide caption

toggle caption

Meredith Rizzo/NPR

Stern’s doctor got a sample of the tumor and sent a genetic analysis of it to what Hopkins calls its “molecular tumor board.” It’s a small group of doctors who meet Mondays to review these genetic tests. They found an overactive gene in his tumor that’s only rarely associated with brain cancer. But that mutation in other cancers sometimes responds to a particular drug. So Ben went on it as part of his ongoing treatment.

“He started his next round of chemotherapy that Monday but he didn’t seem to get weaker,” Tara says, “He was getting stronger almost every day. It was almost miraculous.”

Ben says the drug even reversed his deteriorating mental state brought on by the brain tumor. At the next monthly appointment, following a brain scan, Ben and Tara got more good news.

“The tumor was immeasurable on that next MRI,” Tara says. “It wasn’t there, to put it bluntly.”

Ben’s eyes well up as he hears his wife telling the story. “I was basically as I am now, which is in tears.”

Eight months later, Ben was thinking ahead about his future, rather than wondering whether his life is ending.

Ben and Tara on their wedding day in 2015. The next year, Ben was diagnosed with a brain tumor.

Meredith Rizzo/NPR

hide caption

toggle caption

Meredith Rizzo/NPR

“We have to use this result with caution because we don’t know how long this effect might wear on, but for the time being this is a clinically very meaningful benefit,” says his doctor at Hopkins, medical oncologist Matthias Holdhoff.

And while it’s a good-news story for the field of precision medicine, it is also not the way most of these stories end.

“We’re getting better, but like many things in life, there’s hope and hype. And that’s also the reality with precision medicine right now,” says Ben Park, an oncology professor at the Sidney Kimmel Comprehensive Cancer Center at Hopkins. After noticing how much confusing genetic information was flooding doctors at Hopkins, he founded the molecular tumor board there.

“The reason I started this tumor board [in 2013]… was simply because there was a patient, a young woman who had metastatic breast cancer who had a mutation on one of these reports and decided to forego standard-of-care therapies, which have been proven to actually prolong life in this setting,” Park says. Instead, the woman enrolled in a clinical trial that didn’t really make sense for her particular type of cancer and “she almost died. She had really bad toxicity from the experimental drug.”

She was drawn, Park says, by the allure of precision medicine. Patients and doctors alike are clamoring for these tests. But interpreting the results isn’t easy because different companies offer these tests and interpret the DNA signatures differently, “and that can make a huge difference,” Park says.

“That’s where we’re having difficulty right now as a field,” he says, harmonizing test results that often disagree with each other.

Ben’s tumor recently grew back and he’s now undergoing further treatment.

Meredith Rizzo/NPR

hide caption

toggle caption

Meredith Rizzo/NPR

At Hopkins, the genomic tests usually don’t offer any suggestion for treatment. Only about one quarter of patients at Hopkins are steered toward particular drugs or toward ongoing clinical trials. Other top medical centers find they can identify potential treatments only about 10 percent of the time.

So far there’s only been one randomized study of this approach to precision cancer care — and it did not show a survival advantage for people who went through all this genetic testing.

“If you have this knowledge, it’s not enough,” Park says. “You have to prove that acting on that knowledge — some medical intervention — will actually afford benefit for patients. That’s the trickiest, toughest part about looking at all these types of genomic tests, to really prove that this is making a difference in the lives of our patients.”

Park has since passed on leadership of the molecular tumor board to his colleague, oncologist Josh Lauring. Lauring says there are a few cancers where DNA analysis does make a clear difference, say in melanoma and certain types of lung cancer.

Tara keeps detailed notes of Ben’s progress and also keeps track of his treatment schedule on a daily basis.

Meredith Rizzo/NPR

hide caption

toggle caption

Meredith Rizzo/NPR

“In other cancers, it’s really kind of an open question. At the same time, this testing is available commercially as well as at academic medical centers, and is being done. Patients want it, providers want it.”

So what’s happening, in effect, is a huge, unorganized experiment, involving real patients, treated differently in all sorts of settings. Lauring and colleagues at Hopkins are trying to keep track of all their patients: what treatment they got, how long it was successful, and how long the patients lived.

“We think it’s really important to capture that information as well, to try to learn from it,” Lauring says, “because in many cases it’s not going to be effective, but in some it is, and it’s important for us to figure that out.”

Therapies that target specific genetic patterns are appealing because medical scientists have some sense of the biology underlying their drugs — they aren’t just killing fast-growing cells, as conventional chemotherapy does.

“Unfortunately in many cases these responses, if they occur, are relatively brief.”

That unfortunately turned out to be the case for Ben Stern as well. Five months after his remarkable response, Ben started feeling weaker again. An MRI suggested the cancer might be on the move. So he went back to the hospital for another round of chemotherapy and radiation.

They’re hoping for the best.

Contact Richard Harris at rharris@npr.org.

Let’s block ads! (Why?)